A systematic review and meta-analysis of randomized controlled trials, juxtaposing the control of glycemia and blood pressure between large dose empagliflozin and placebo among type 1 diabetes patients.
Year: 2020
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: OBJECTIVES: While empagliflozin (25 mg) is used to treat type-2 diabetes mellitus patients with optimum renal functioning, its efficacy and safety in type-1 diabetes mellitus (T1DM) is not yet established. Therefore, this study aimed to compare insulin-treated T1DM patients' (with adequate renal functioning) glycemic and blood pressure control between the 25 mg empagliflozin recipients and placebo recipients. METHODS: or more were eligible for inclusion. Trials were searched in PubMed, EMBASE, SCOPUS, and CENTRAL with no restriction on date and language. Risk of bias of trials was assessed and mean and standard deviation of glycated hemoglobin (HbA1c, in %), systolic blood pressure (mmHg), and diastolic blood pressure (mmHg) at the end of the trial period were collected, and random-effects meta-analysis was done to estimate the weighted mean difference (WMD). The meta-analysis was done in Stata statistical software. This study was conducted in June 2019. RESULTS: = 0%). The WMD of blood pressure (systolic and diastolic) did not vary between the treatment groups. CONCLUSION: Evidence (of moderate quality) suggests that daily administration of empagliflozin 25 mg tablets in adjunct to insulin in T1DM patients with optimum kidney functioning is useful to achieve glycemic control compared to placebo and insulin therapy. However, the effect on blood pressure remained indistinguishable between the compared interventions.
Source: PubMed
Authors: Sumanta Saha, Sujata Saha
Institution: National Institute of Research in Tuberculosis
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3012742907